InnaCell Therapeutics

Clinical Case Reviews

Case Study Summaries Using InnaCell Therapeutics

1. Clinical Case Review – Dementia (90-year-old female)

A case of a 90-year-old Caucasian female with progressive dementia, hypertension, and type 2 diabetes.

  • Details
    • Patient treated with nebulized MSC exosomes (IV and nebulized), followed by MUSE cell-derived exosomes (nebulized) and U cells (IV). After the third treatment, significant improvement in orientation, recognition of family, and simple phrase construction was observed. Improvements sustained at 6- and 12-month follow-ups, with improved ambulation and care compliance.
  • Conclusion
    • Protocol of MSC and MUSE exosomes demonstrated sustained cognitive and functional improvement in advanced dementia.

2. Clinical Case Review – Multiple Sclerosis

A 59-year-old Caucasian woman diagnosed with MS at age 39, having failed all conventional treatments.

  • Details
    • Patient presented with motor and sensory deficits on the left side, near-complete blindness in the left eye, aphasia, and limited fine motor movement.
    • Treated with MUSE exosomes (IV and nebulized), followed by MUSE cell-derived exosomes (100 billion per session, 4 treatments every 2 weeks), then 2 infusions of MUSE cells (15 million IV, one month apart).
    • Adjunct peptides used included humanin and thymalin targeting autoimmune processes and neuroprotection. Neuropathic pain reduced from 8/10 to 3/10. Patient in remission for one year.
  • Conclusion
    • Combination of MUSE exosomes, MUSE cells, and peptides produced major, sustained improvements across motor, sensory, visual, and cognitive domains.

3. Clinical Case Review – Rare Genetic Mutation

A 33-year-old female with a rare genetic mutation affecting basal membranes in the kidney, skin, and lungs.

  • Details
    • Patient required kidney transplant and developed pulmonary fibrosis as a young adult.
    • Treatment involved anti-fibrotic peptides, followed by MUSE cells incubated with patient macrophages and fibroblasts, applied nebulized and systemically.
    • Resulted in improved VO2 max, reduced pulmonary fibrosis, and improved eGFR. Patient is a candidate for gene therapy. Described as one of very few such cases in the world.
  • Conclusion
    • Multi-layered protocol with peptides and MUSE cells achieved sustainable remission and improvement in both pulmonary and renal function in an extremely rare condition.

4. Clinical Case Review – Stage 4 Paget Disease

An 85-year-old former physician with stage 4 Paget disease (male breast cancer), having failed 3 chemotherapy courses with metastatic spread to liver, retroperitoneal area, and mesenteric lymph nodes.

  • Details
    • Treated with autologous NK cells derived, expanded, and transfused from his own blood. PET scan 2 months post-treatment showed 50% reduction in metastatic node size. Disease stabilized for one year; repeat treatment led to further reduction and arrest of all metastatic node growth.
  • Conclusion
    • Autologous NK cell therapy demonstrated significant anti-tumor response.

5. Clinical Case Review – Hemorrhagic Stroke

A 62-year-old former football player with a recent major hemorrhagic stroke causing significant motor impairment and loss of speech.

  • Details
    • Treated one-week post-stroke with IV injections of small mobile cells (a novel stem cell line), 400 million cells per infusion, 2 infusions total.
    • Patient regained speech within a few weeks with no aphasia and recovered motor deficits within 4 weeks, exceeding known neurological recovery benchmarks in both speed and extent.
  • Conclusion
    • Small mobile cells showed exceptional results in acute stroke recovery.

6. Clinical Case Review – Renal Transplant Rejection

A 34-year-old Asian male with IgA nephropathy who received a renal transplant 3 years prior and developed signs of ongoing rejection.

  • Details
    • Patient was on cytostatics and developing rejection markers. Treated with MUSE cells, which, due to their near-absent HLA marker expression, were able to penetrate the damaged transplanted kidney, absorb fragments of damaged cells, and potentially modulate immune cells.
    • Treatment led to stabilization of graft function.
    • The mechanism involves MUSE cells homing to damaged tissue, absorbing damaged cell fragments, and potentially modulating immune cell populations rather than eliminating rejection outright.
  • Conclusion
    • MUSE cells demonstrated a stabilizing effect on renal transplant rejection through a unique, non-immunosuppressive mechanism.

7. Clinical Case Review – Long COVID with CKD

A patient with long COVID affecting kidney function, with pre-existing hypertension, type 2 diabetes, and CKD stage 3.

  • Details
    • Baseline creatinine approximately 1.6. Treatment protocol included plasmapheresis (to remove antibodies and spike proteins), followed by MUSE cell-derived exosomes (500 billion twice weekly), then MUSE cells (50 million IV, then 100 million IV).
    • Post-treatment eGFR improved to 56 and creatinine dropped to 1.3. Brain fog resolved. Adjunct peptides targeting fibrosis, inflammation, and regeneration were also used.
    • The use of mitochondrial peptides, humanin, thymalin, and peptides targeting fibrotic conditions and kidney regeneration.
  • Conclusion
    • Combined plasmapheresis, exosome, MUSE cell, and peptide protocol produced significant renal and neurological improvement in long COVID.

8. Clinical Case Review – Muscular Dystrophy with Behavioral Issues

A 12-year-old child with back muscular dystrophy, behavioral problems, spasticity, and communication difficulties, having previously received approximately 12 MSC treatments with diminishing returns.

  • Details
    • Alexander: Treatment initiated with MUSE cell-derived exosomes to prepare terrain and benefit from blood-brain barrier penetration. Patient showed reduced agitation and more relaxed posture.
    • Subsequent intranasal MUSE cell application was introduced once patient was calmer, followed by MUSE cell IV transfusions. Patient also received subcutaneous injections of FDA-approved peptide SS31.
    • Results included decreased spasticity, improved muscle mass, and significant neurobehavioral improvement including better interpersonal tolerance and response to verbal instructions.
  • Conclusion
    • Stepwise MUSE exosome and cell protocol, combined with SS31 peptide, produced meaningful functional and behavioral improvements where prior MSC therapy had plateaued.

9. Metabolic Syndrome, Obesity, and Type 2 Diabetes Cases

  • Details
    • Protocols involved mitochondrial peptides in a defined sequence: humanin (mitochondrial function and anti-apoptosis), SS31 (sarcopenia), MOTC (mitochondrial autophagy/rejuvenation), and humanin-like small peptide 2 (metabolic flexibility and insulin sensitivity).
    • Plasmapheresis used to improve microenvironment and receptor sensitivity. Low-dose GLP-1 combined with improved receptor sensitivity achieved better outcomes with fewer side effects. Pituitary axis peptides (GHRH, GHRP) used to improve lean body composition.
  • Conclusion
    • A structured mitochondrial peptide protocol, combined with plasmapheresis and low-dose GLP-1, offers a comprehensive metabolic optimization service with sustained results and reduced adverse effects.

10. Clinical Case Review – Pediatric Immune Deficiency

A young male with chronic recurrent infections, neuroinflammation, low body weight, and undiagnosed immunodeficiency.

  • Details
    • Conventional medicine and genetic testing failed to identify a specific mutation. Treatment began cautiously with humanin, thymalin, and plasmapheresis to modulate (not stimulate) the immune system. Thymogen alpha-1 and thymogen were introduced, followed by mitochondrial peptides to support immune cell function.
    • NK cell-derived exosomes were used intranasally and IV. Patient stopped having recurrent infections, neuroinflammation resolved, focus and concentration improved significantly.
    • Patient completed high school with high scores and enrolled in college. Mild growth support provided with ipamorelin and CJC. Now 19, healthy, active, and thriving.
  • Conclusion
    • A gradual, layered immune modulation protocol using peptides and NK cell-derived exosomes successfully resolved chronic immune deficiency and neuroinflammation without identifying a specific genetic cause.

11. Clinical Case Review – Elderly Patients with Chronic Immune Dysregulation

Brief mention of elderly patients with chronic sinusitis, bronchitis, elevated white blood cell counts, and early autoimmune markers.

  • Details
    • Responded well to peptides first harmonizing the immune system, then mildly increasing immune activity. Improvements seen across all organ systems.
  • Conclusion
    • Peptide-based immune harmonization is effective for age-related immune dysregulation.

12. Clinical Case Review – COVID-19 Brain Coma

A 29-year-old woman who developed respiratory failure and brain coma following acute COVID-19.

  • Details
    • Administered MUSE cell-derived exosomes intranasally (100 billion twice weekly) while patient was in a rehabilitation center. After 2 weeks, patient became responsive and began opening her eyes. Within 4 weeks, she was participating in physical therapy and communicating with increasingly organized speech. Continued to improve steadily.
  • Conclusion
    • Intranasal MUSE cell-derived exosomes demonstrated remarkable efficacy in reversing COVID-19-induced brain coma.

13. Clinical Case Review – Hypertensive Retinopathy with Retinal Hemorrhage

A brief case of a patient with severe hypertension and retinal hemorrhage causing vision loss.

  • Details
    • Treated with MUSE cells. Retina healed and vision returned to the damaged eye after a couple of treatments.
  • Conclusion
    • MUSE cells showed regenerative potential for retinal damage secondary to hypertensive retinopathy.